CytomX Therapeutics Inc (NASDAQ:CTMX) shares, rose in value on Friday, March 28, with the stock price up by 1.88% to the previous day’s close as strong demand from buyers drove the stock to $0.63.
Actively observing the price movement in the last trading, the stock closed the session at $0.62, falling within a range of $0.5906 and $0.6306. The value of beta (5-year monthly) was 1.043 whereas the PE ratio was 1.60 over 12-month period. Referring to stock’s 52-week performance, its high was $5.85, and the low was $0.56. On the whole, CTMX has fluctuated by -6.96% over the past month.
With the market capitalization of CytomX Therapeutics Inc currently standing at about $50.32 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-05.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 101.2M, with a low estimate of 12.5M and a high estimate of 38.5M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 28.52M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CTMX’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CTMX currently trading nearly -1.01% and -15.32% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 43.15, while the 7-day volatility ratio is showing 6.03% which for the 30-day chart, stands at 8.59%. Furthermore, CytomX Therapeutics Inc (CTMX)’s beta value is 1.36, and its average true range (ATR) is 0.05.
A comparison of CytomX Therapeutics Inc (CTMX) with its peers suggests the former has fared considerably weaker in the market. CTMX showed an intraday change of 1.88% in last session, and over the past year, it shrunk by -70.23%%.
Data on historical trading for CytomX Therapeutics Inc (NASDAQ:CTMX) indicates that the trading volumes over the past 10 days have averaged 1.01 and over the past 3 months, they’ve averaged 1.83 million. According to company’s latest data on outstanding shares, there are 80.10 million shares outstanding.
Nearly 2.46% of CytomX Therapeutics Inc’s shares belong to company insiders and institutional investors own 58.45% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 9.0 million shares as on 2025-03-14, resulting in a short ratio of 2.52. According to the data, the short interest in CytomX Therapeutics Inc (CTMX) stood at 1132.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 4.4 million. The stock has fallen by -39.01% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CTMX stock heading into the next quarter.
